Table 2.
Degree of ALS-affected relative used to define fALS | Population-based studies | fALS cases | Total ALS | Estimate (lower limit, upper limit) |
Europe | ||||
First-degree | 4 | 18 | 424 | 0.05 (0.03, 0.07)a |
First or second-degree | 3 | 16 | 194 | 0.09 (0.05, 0.15)a |
First or second-degree or more distant | 1 | 50 | 444 | 0.11 (NA, NA) |
North America | ||||
First-degree | 4 | 324 | 6,985 | 0.05 (0.04, 0.05)a |
First or second-degree | 1 | 49 | 946 | 0.05 (NA, NA) |
First or second-degree or more distant | 0 | NA | NA | NA |
Overall | ||||
First-degree | 9 | 344 | 7,512 | 0.05 (0.04, 0.05)a |
First or second-degree | 4 | 65 | 1,140 | 0.07 (0.04, 0.11)a |
First or second-degree or more distant | 1 | 50 | 444 | 0.11 (NA, NA) |
Abbreviation: ALS = amyotrophic lateral sclerosis; NA = not applicable.
Random-effects meta-analytic estimates and corresponding 95% confidence intervals are presented (>2 and I2 < 90%). Otherwise, weighted averages and ranges are presented.